Literature DB >> 19962852

[Epidemiology of interstitial lung diseases].

Dominique Valeyre1, Olivia Freynet, Geneviève Dion, Diane Bouvry, Isabella Annesi-Maesano, Hilario Nunes.   

Abstract

Diffuse interstitial lung diseases (DILD) cover more than 200 conditions classified in 4 groups: secondary DILD; sarcoidosis; particular DILDs and idiopathic interstitial pneumonias. Overall, these diseases have a prevalence of 60-80/100,000 and an incidence around 30/100,000. Sarcoidosis and idiopathic pulmonary fibrosis are the 2 most frequent diseases, accounting together for more than 50% of all cases, followed by DILD related to connective tissue disease and to immunologic lung diseases. The incidence of different causes of DILD depends on epidemiologic factors: age, sex, race, smoking habits, and history. Mortality is very elevated in idiopathic pulmonary fibrosis, linked in more than 80% of cases to the fibrosis itself, with a median survival between 24 and 36 months. The epidemiologic studies on DILD have substantial limitations, and new studies must be conducted, in particular in France where we lack epidemiologic data beyond one old study of sarcoidosis and one more recent study focused on farmer's lung in the Doubs. Copyright 2009 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19962852     DOI: 10.1016/j.lpm.2009.09.015

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  2 in total

1.  Daily life physical activity in patients with chronic stage IV sarcoidosis: A multicenter cohort study.

Authors:  Sarah Froidure; Maeva Kyheng; Jean Marie Grosbois; Francois Lhuissier; Sandrine Stelianides; Lidwine Wemeau; Benoit Wallaert
Journal:  Health Sci Rep       Date:  2019-01-15

2.  Spiruchostatin A inhibits proliferation and differentiation of fibroblasts from patients with pulmonary fibrosis.

Authors:  Elizabeth R Davies; Hans Michael Haitchi; Thomas H Thatcher; Patricia J Sime; R Matthew Kottmann; Arasu Ganesan; Graham Packham; Katherine M A O'Reilly; Donna E Davies
Journal:  Am J Respir Cell Mol Biol       Date:  2012-01-12       Impact factor: 6.914

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.